TOKYO -- Japanese pharmaceutical company Eisai is developing a blood test to determine whether patients with Alzheimer's disease can benefit from lecanemab, marking another step in its efforts to expand its dementia treatment and care business.
Pharmaceuticals
Japan's Eisai eyes blood test for Alzheimer's drug eligibility
Drugmaker looks to lower hurdles to use of potential blockbuster treatment
Eisai targets more than $350 million in global Leqembi sales this fiscal year. (Eisai)
Read Next
Latest on Pharmaceuticals
